Regnase-1 Promotes Tumour-Initiating Activity in Non-Small Cell Lung Cancer
The Journal of Biochemistry · 2026
DOI: 10.1093/jb/mvaf061 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Biochemistry, 2026. Verfasst von Keito Okazaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ribonucleases, Transcription Factors. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Kobayashi Foundation for Cancer Research, MSD-life-science-Foundation, JSPS.
Abstract (Originalsprache)
Regnase-1, encoded by the ZC3H12A gene, is a well-known RNase that suppresses inflammation by degrading the mRNAs of inflammatory cytokines. However, its role in cancer pathogenesis, especially in non-small cell lung cancer (NSCLC), remains poorly understood. Through an analysis of public databases, we found that NSCLC patients with higher ZC3H12A expression levels had a worse prognosis than those with lower levels. To explore the function of Regnase-1 in NSCLC, we knocked out the ZC3H12A gene in NSCLC cell lines and compared their transcriptomes with those of parental cells. This analysis identified the SOX2 pathway as a common pathway suppressed by Regnase-1 deficiency. Consistent with the SOX2 contribution to the cancer stemness, Regnase-1 inhibition impaired oncosphere growth and tumour formation of cell lines derived from adenocarcinoma, squamous cell carcinoma and large cell carcinoma. It was also effective for NRF2-activated NSCLC cells, which are highly resistant to most of the therapeutics. Notably, post-tumorigenic suppression of Regnase-1 significantly inhibited tumour growth, suggesting that Regnase-1 could be a promising therapeutic target for post-tumorigenic treatment of NSCLC. Given recent studies describing that Regnase-1 inhibition enhances anti-cancer immunity, we propose that targeting Regnase-1 could be an ideal strategy for controlling intractable cancers by both suppressing cancer cells and activating anti-cancer immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
- Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
- Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Yoshida Konoemachi, Sakyo-ku, Kyoto 606-8501, Japan.
ORCID-Profile: Osamu Takeuchi
Förderung
- Kobayashi Foundation for Cancer Research
- MSD-life-science-Foundation
- JSPS
Zitieren
APA
Okazaki, K., Kawaguchi, M., Murakami, S., Takeda, H., Sekine, H., Takeuchi, O., & Motohashi, H. (2026). Regnase-1 Promotes Tumour-Initiating Activity in Non-Small Cell Lung Cancer. The Journal of Biochemistry. https://doi.org/10.1093/jb/mvaf061
Vancouver
Okazaki K, Kawaguchi M, Murakami S, Takeda H, Sekine H, Takeuchi O, et al. Regnase-1 Promotes Tumour-Initiating Activity in Non-Small Cell Lung Cancer. The Journal of Biochemistry. 2026. doi:10.1093/jb/mvaf061
BibTeX
@article{Okazaki2026,
author = {Okazaki, Keito and Kawaguchi, Madoka and Murakami, Shohei and Takeda, Haruna and Sekine, Hiroki and Takeuchi, Osamu and Motohashi, Hozumi},
title = {Regnase-1 Promotes Tumour-Initiating Activity in Non-Small Cell Lung Cancer},
journal = {The Journal of Biochemistry},
year = {2026},
doi = {10.1093/jb/mvaf061}
}
EUVIMED